The t(12;21)(p13;q22) is the most common translocation in childhood B-precursor ALL. It results in a TEL-AML1 rearrangement and is associated with a good prognosis. Because many chromosomal alterations in leukemia are associated with distinct cell surface phenotypes, we investigated whether there was an association seen between surface marker expression and the TEL-AML1 rearrangement. Of 166 unselected cases of B-precursor ALL studied by Southern hybridization, 45 cases (27%) showed TEL rearrangement. Blasts of patients with TEL rearrangement were much more likely to be CD9-negative, CD45-positive, CD13 positive, and CD20 negative, but the predictive value of any of these markers for the rearrangement was very low. However, 93% of patients with the TEL rearrangement had blasts that were either negative or only partly positive for CD9; this phenotype was only seen in 27% of patients without the rearrangement. Only information about CD20 expression added to the predictive value of CD9 alone. The predictive value of the phenotype CD9 (negative or partly positive) and CD20 (negative or partly positive), for the TEL rearrangement was prospectively tested on an additional 223 cases, and found to be 88% sensitive and 71% specific for the rearrangement, with a positive predictive value of 47%. Hyperdiploidy, previously shown to correlate negatively with the rearrangement, was a slightly more sensitive indicator (94%) but had a much lower predictive value (28%). Three of eight cases found to be rearranged by Southern hybridization but lacking the characteristic phenotype failed to show evidence of the TEL-AML1 rearrangement by polymerase chain reaction, suggesting that at least some of the discordant cases may involve partner genes other than AML1 in the TEL rearrangement. We conclude that immunophenotyping is highly predictive of the TEL rearrangement. For every 100 patients with B-precursor ALL, we estimate that prescreening by phenotyping would eliminate the need for molecular testing on 57 patients and only two or three of an expected 24 patients with the TEL rearrangement would not be detected. Keywords: childhood; acute lymphoblastic leukemia; TEL; AML1; flow cytometry
Introduction
The TEL-AML1 fusion, created by a cryptic t (12;21) , is the most common translocation in childhood ALL, occurring in about 25% of cases. [1] [2] [3] Patients with this translocation have a favorable prognosis. [4] [5] [6] Blast cell hyperdiploidy, another important favorable prognostic factor, is negatively correlated with the presence of this translocation, 2, 5, 6 so that these two favorable genetic characteristics identify separate subsets of children. Although the TEL-AML1 translocation is restricted to patients with B-precursor ALL, and specifically to common ALL, 4, 6 relatively little additional information is available about the blast cell characteristics of these cases. of blast cells. [7] [8] [9] [10] [11] [12] [13] [14] These distinctive phenotypic properties are sometimes morphological, particularly in the case of AML, with close associations between morphology and abnormalities in transcription factors affecting the AML1-CBF-␤ complex. 10, 12 In ALL, T and B-lineage leukemias appear to involve unique transcription factors, 15 and among cases of B-precursor ALL there have also been more detailed associations found between expression of specific differentiation-associated surface molecules and particular translocations. 13, 14 Because the AML1 gene is an important regulator of differentiation, and because abnormalities in this gene have been shown to be associated with specific phenotypic abnormalities in AML, 12 we undertook a study to determine if a specific pattern of expression of B cell-associated differentiation antigens could be seen in association with the TEL-AML1. Our results indicate that blasts at the differentiation stage characterized by complete or partial lack of both CD9 and CD20 were highly likely to have TEL rearrangements; this phenotype can be used to predict cases of abnormal TEL with a high sensitivity and moderate specificity.
Materials and methods

Patient population
The subjects in this study consisted of two groups of patients who constituted a subset of those entered on the POG 9400 classification study for newly diagnosed childhood ALL, from June 1996 to December 1996. After signing informed consent, all patients whose blasts were determined to be negative for myeloperoxidase and nonspecific esterase by locally performed standard cytochemistry had aliquots of bone marrow sent to the immunophenotyping reference laboratory at Johns Hopkins University, and to the reference laboratory of St Jude Children's Research Hospital for ploidy studies 116 and for cell banking. A subset of patients with confirmed B-precursor ALL for whom excess material was available were studied for TEL rearrangements. Over the period of this study, 78% of patients had sufficient material to complete these studies.
Immunophenotyping
Samples received at the Johns Hopkins reference laboratory were phenotyped by three color immunofluorescence flow cytometry using a modification of previously published dual color procedures, 17 except that a whole marrow lysis procedure was employed, and CD45-perCP was used as a common reagent to permit specific isolation of the blast population for gating. 18 Cases were prescreened either at local institutions or with the combination of CD45, CD19 and CD10 to identify likely cases of B-precursor ALL. All such cases were studied with a reagent panel of phycoerythrin and FITC conjugates as follows: CD19-PE/CD10-FITC; HLADR-PE/CD7-FITC; CD20-PE/CD34-FITC; CD9-PE/CD24-FITC;  CD33-PE/CD71-FITC; CD13-PE/CD15-FITC. In addition, a separate two-color analysis of CD22-PE/CD45-FITC was performed. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA) except for CD19-PE (Immunotech, Westbrook, ME, USA) and CD9-PE and CD24-FITC (Pharmingen, San Diego, CA, USA).
Flow cytometric analysis was performed on a FACScan flow cytometer equipped with a 488 nm laser. Instrument settings were initially established using standard Calibrite beads (Becton Dickinson), but then refined to minimize day-to-day variability using QC3 beads (Flow Cytometry Standards, San Juan, PR). Analysis was performed using CellQuest software, first gating on displays of CD45 and right angle scatter to isolate the blast population, and then displaying either dual parameter dot plots or single parameter histograms of expression of antigens on the blasts.
Cases were defined as B-precursor ALL based on bright uniform expression of CD19 on the CD45-gated blast population; in rare cases CD19 was negative or partly expressed, but the case was still considered B-precursor ALL because of bright uniform expression of CD22. Antibody positivity was determined by comparison of the shape of either histograms or dot plots to those of control nonreactive antibodies. 19 Initially, each antibody was categorized simply as positive or negative based on whether the histogram showed a significant shift (usually a minimum of 80-100 channels on a 4 decade log scale) relative to nonreactive antibodies, or if a distinct subset of the gated blasts, generally amounting to at least 10% of cells, showed expression that was clearly above the threshold determined by consideration of the reactivity of the control antibody. In subsequent analyses, these two patterns were distinguished, and cases in which only a subset of cells were seen to be positive was referred to as having 'partial' positivity. Figure 1 demonstrates typical reactivity patterns of histograms considered positive, negative and 'partial' positive in the case of CD9 expression. As illustrated, these histograms were generated based on gating of CD45/RALS displays to isolate leukemic blasts, and thus represent true distributions of antigen distribution on blast populations. Other antibodies generally showed similar patterns, though in some cases of partial positivity the positive events constituted a majority of the blast population, rather than the minority, as shown in the Figure.
In an initial exploratory analysis, immunophenotyping data were reviewed in detail on 166 patients with B-precursor ALL whose TEL status was known. In this retrospective analysis, significant associations could be seen with several antigens, but the relationship between combinations of antigens and phenotype was investigated in sufficient detail to try to determine a phenotype which might predict the presence of the TEL rearrangement. The accuracy of the phenotype was then validated by having one of us (MJB) send predictions on a subsequent series of 223 patients without regard to TEL status to the St Jude laboratory for correlation.
TEL rearrangements
Genomic DNA was analyzed for TEL gene rearrangements as previously described. 2 Briefly, 10 g of high molecular weight DNA was digested with BamHI, separated electrophoretically in 0.8% agarose gels, and transferred to nylon membranes. Membranes were then hybridized with an ␣-32 P-dCTP-labeled 466-bp SacI/BamHI TEL cDNA fragment. 2 After high stringency washes, membranes were analyzed by autoradiography. A subset of the samples that demonstrated TEL rearrangement by Southern blot were analyzed by reverse-transcriptase polymerase chain reaction (RT-PCR) for the expression of the der(21)-encoded TEL/AML1 fusion transcript using described amplification primers and probes. 2 
Statistics
Comparisons of frequencies were made using the 2 test. Sensitivity, specificity and predictive value were calculated with standard formulas using the presence of a TEL gene rearrangement as the desired outcome to be predicted.
Results
One hundred and sixty-six cases of B-precursor ALL in which there was sufficient material after completing the required studies for the POG ALL protocols were studied by Southern hybridization to detect rearrangements of the TEL gene. Fortyfive of these cases (27%) showed TEL rearrangements. The results of these studies were correlated with immunophenotype, as shown in Table 1 . Immunophenotyping was satisfactory in 159/166 cases including all of the cases with TEL rearrangements. There was no correlation between TEL rearrangements and expression of CD19, CD10, HLADR, CD22, CD24 or CD33. However, the other markers tested showed statistically significant associations with TEL rearrangements. Blasts of patients with TEL rearrangements were much more likely to be CD9-negative and CD45-positive, and somewhat more likely to be CD13-positive or CD20-negative. However, there was considerable heterogeneity seen, and the predictive value of any of these markers for the TEL rearrangement was very low. For example, although 97% of TEL+ cases were CD45-positive, 78% of TEL-negative ones were positive as well; thus, in spite of the statistically significant association the specificity of CD45 positivity for a TEL rearrangement was very low.
To try to improve the predictive value, the immunophenotypic information was examined in more detail, as described in the materials and methods (Table 2) . When looked at in this manner, CD34 expression was also shown to be correlated with TEL rearrangements. Moreover CD9, which was already shown to show a highly significant statistical association with TEL rearrangements when only a simple distinction between positive and negative was made, now demonstrated a pattern that was much more useful as a predictor for the rearrangement. Thus, 93% of patients with TEL rearrangements had blasts that were either CD9-negative, or only partially positive; by contrast only 27% of patients whose blasts lacked TEL rearrangements had this phenotypic pattern. Although positivity for CD45, or complete or partial absence of CD20 were more sensitive markers for the rearrangement, both were very nonspecific. CD9-positivity and CD45-negativity were highly correlated (data not shown) so that combining both of these markers did not enhance the specificity or sensitivity above that of CD9 alone. Similarly, the relatively low sensitivity of CD13 or CD34 expression for the rearrangement made it impossible to use information about these antigens to improve the predictive value of the CD9 phenotype. However, review of cases classified as CD9-negative or partly positive revealed eight additional cases that were CD20-positive; as no CD20-positive case was TEL-rearranged, CD20- positive cases could be eliminated and thus improve the specificity of the determination at no cost to the sensitivity.
To investigate whether this algorithm could serve as a means for predicting cases of TEL rearrangements, the immunophenotype of an additional series of cases of B-precursor ALL was reviewed in detail without knowledge of TEL status. Cases were considered TEL phenotype-positive if their blasts were either negative or only partly positive for CD9, and also negative or partly positive for CD20. Other combinations were considered TEL phenotype-negative. Satisfactory TEL studies were available on a total of 223 of these cases. As shown in Table 3 , the phenotype was highly predictive of the TEL rearrangement in this prospective series of additional cases.
PCR analysis of TEL-AML1 fusion
Although the most common TEL rearrangement in B-precursor ALL involves AML1 on chromosome 21 as the partner gene, other rearrangements have been seen, [20] [21] [22] [23] and it is not clear that they should be expected to display the same phenotype. To investigate this possibility, eight cases of TEL rearranged leukemia not predicted by the immunophenotypic profile (including the six cases identified in Table 3 plus two additional false negative cases from the first series of patients) were tested by RT-PCR for the presence of the TEL-AML1 fusion transcript. Five of these cases expressed TEL-AML1, whereas three showed no evidence of the fusion transcript. It 
Correlation of phenotype and ploidy
Previously it has been recognized that hyperdiploidy showed a significant negative correlation with TEL status. 2, 5, 6 We therefore investigated the relationship between ploidy status and immunophenotype in our prospectively defined data set. Fifty-four of 222 cases were hyperdiploid; only five of these hyperdiploid cases were phenotype-positive. Interestingly, three of the five hyperdiploid cases were TEL rearranged. Only 48 of 169 non-hyperdiploid cases showed TEL rearrangement; thus the predictive value of (lack of) hyperdiploidy for the TEL rearrangement was substantially lower than that of immunophenotype (28 vs 47%), though the sensitivity and specificity were similar. Because of the high correlation between ploidy status and phenotype, and the lack of complete specificity of ploidy, adding information about ploidy did not improve the predictive value of immunophenotype alone.
Discussion
Many types of acute leukemia are associated with production of abnormal transcription factors that control specific steps in hematopoietic cell differentiation. One manifestation of differentiation is the expression of stage-specific and lineage-specific surface membrane proteins. This has led to the observation that many types of acute leukemia associated with specific translocations are associated with characteristic immunophenotypes. 8, 10, 12, 14 In this study, we demonstrate that childhood ALL associated with the TEL-AML1 can be added to the list of such leukemias.
Cases of ALL with rearranged TEL genes had a characteristic immunophenotype in which their blasts failed to express homogeneous CD20 or CD9 in nearly all cases. CD20 is known to be an antigen expressed relatively late in B cell development; there are no good studies which speak to the pattern of acquisition of CD9. In preliminary experiments, however, we have shown that in normal B cell differentiation the earliest CD34 + B cell precursors are CD9-negative or low density, and that CD9 acquisition roughly follows that shown by CD20 (Borowitz et al, unpublished) . Although the AML-1 gene is known to be of critical importance in the regulation of myeloid differentiation 24 less is known about its possible role in lymphoid development. Certainly there are no data to suggest that either CD20 or CD9 are potential target genes for the AML1 gene product. CD9, a member of the tetraspan superfamily of cell surface molecules involved in cell adhesion, has been shown to be upregulated in response to TPA-induced differentiation in HL60 cells. 25 Although the close association between TEL-AML1 fusion and a common ALL phenotype has been well recognized, 2, 5, 6 there has been relatively little work exploring correlation between detailed blast cell phenotypic characteristics and this molecular abnormality. Borkhardt et al 6 have shown a statistically significant correlation with myeloid antigen expression including CD13, a result which was confirmed in a recent study of Baruchel et al 26 who also showed a correlation with CD33 expression. Our results confirm a correlation with CD13, but not CD33. We also found statistically significant correlations with expression of CD34 and CD45 which were not previously noted in these other studies. In addition, we further addressed the question of the predictive value of immunophenotype, a much more stringent test of association than a simple statistically significant association. In fact, we found that many of the markers that were statistically associa-ted with TEL rearrangements had little power to predict the presence of the rearrangement.
The results of this study extend our previous work showing correlations between immunophenotype and cytogenetic and molecular genetic abnormalities involving the MLL gene 13 or the E2A-pbx1 translocation in pre-B ALL.
14 These studies share two properties with the current study. First, accurate phenotypic predictions could not be obtained by simply classifying antigen expression as either positive or negative. More complex descriptions of patterns of expression of combinations of antigens was required to demonstrate significant predictability. In the most predictive algorithm in the current study, blasts that partially expressed either CD9 or CD20 were best considered with those that completely lacked the antigens. This same characteristic was seen in the predictive value of CD20 expression for the E2A-pbx1 translocation.
14 The algorithm defined in that study, however, required that CD9 be expressed in a bright, homogeneous pattern. Interestingly, myeloid leukemias associated with translocations involving the AML1 gene are also associated with a distinctive immunophenotype, though not surprisingly different antigens are involved. 12 The second common feature that our current findings on the TEL-AML1 share with prior studies is that the algorithm was not a perfect predictor of the genotype. The reasons for this are not clear, though the group of patients that phenotyping fails to predict are of potential great interest. The TEL-AML1 translocation is well known to be associated with an excellent prognosis. It is worth recognizing, however, that disease behavior is fundamentally a phenotypic characteristic. Though many more patients will be required to address this question, it would be of interest to determine if the few patients with TEL rearrangements without the phenotype we describe here fare as well as the larger group.
It should be noted that although we employed qualitative assessments of histogram shape to help classify tumors in this study, we did not employ quantitative analysis of antigen expression which we had previously done in other studies. 17 In those studies, quantitative analysis was important because, in contrast to these studies, there were few differences seen between positives and negatives, and important differences were seen between high density expression and low. Nevertheless, it remains possible that the correlations we describe here could be improved by such quantitative studies.
In previous studies, 2, 5 we found that greater than 90% of cases that demonstrated rearranged TEL also expressed TEL-AML1. In this study, we selectively looked at patients in whom we failed to predict the TEL rearrangement by our phenotypic algorithm, and found three of eight cases that were negative by RT-PCR. It should be noted that TEL may rarely be fused to other genes in B-lineage ALL. [20] [21] [22] [23] It would be of interest to know if any of these other candidate partner genes were involved in these three cases. Though the numbers are small, selection by immunophenotype appeared to identify a significantly larger fraction of cases with discordance between the Southern and PCR results than was seen in our previous study. This suggests that the phenotypic algorithm we propose may be even more highly correlated with the TEL-AML1 translocation than with TEL rearrangements.
Although more still needs to be done to determine the biologic significance of the association we describe here, our results have immediate practical consequences. Because the TEL-AML1 translocation is an important independent favorable prognostic marker, 2,4,6 many new studies of childhood ALL will require this measurement for assigning patients to therapy. The specificity of our phenotype for the genetic abnormality is only about 70%, but the sensitivity is nearly 90% for predicting TEL rearrangements, and an estimated 92-93% for predicting TEL-AML1 translocation. This suggests that phenotyping could be used as a screening test for the genetic abnormality. Assuming a prevalence rate for this translocation of 24%, our results suggest preliminary immunophenotypic analysis can eliminate the need for molecular testing in 57% of patients. Out of 100 patients with B-precursor ALL, only 3/24 patients harboring TEL rearrangements, or only two with the TEL-AML1 translocation will not be detected. It should be cautioned however, that use of this strategy is dependent upon accurate assessment of the patterns of antigen expression described above, and that the reproducibility of this pattern determination among phenotyping laboratories has not been established. Nevertheless, when our results are combined with our earlier findings correlating immunophenotype and other clinically important translocations, they suggest a more costeffective method for classifying children with B-precursor ALL into important biologically defined risk groups. 
